Interleukin-2 (IL-2) and its receptor (IL-2R) are proteins that play a major role in the regulation of the immune system. IL-2 is a cytokine, a type of small protein secreted by immune cells that can act as a signal to other cells. IL-2R is a transmembrane protein that binds to IL-2 and transmits the signal to the cell. The IL-2/IL-2R system is important for the development and activation of T cells, which are a type of white blood cell that helps to fight infection.
IL-2 and IL-2R can also be targeted with antibodies, which are proteins produced by the immune system to recognize and bind to foreign molecules. Antibodies that target IL-2 and IL-2R can be used to modulate the immune system and treat autoimmune diseases.
IL-2 and IL-2R have also been identified as potential drug targets for the treatment of cancer. IL-2 has been used in the treatment of some types of cancer such as metastatic renal cell carcinoma and metastatic melanoma, and IL-2R has been identified as a potential target for cancer immunotherapy.
ProteoGenix is a biotechnology company that specializes in the production of recombinant IL-2 and IL-2R proteins. ProteoGenix has developed a proprietary technology platform for the production of recombinant proteins, which allows for the production of high-quality proteins with great efficiency.
